MX2022000036A - Proceso para la preparacion de un inhibidor de fosfodiesterasa (pde4). - Google Patents
Proceso para la preparacion de un inhibidor de fosfodiesterasa (pde4).Info
- Publication number
- MX2022000036A MX2022000036A MX2022000036A MX2022000036A MX2022000036A MX 2022000036 A MX2022000036 A MX 2022000036A MX 2022000036 A MX2022000036 A MX 2022000036A MX 2022000036 A MX2022000036 A MX 2022000036A MX 2022000036 A MX2022000036 A MX 2022000036A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- relates
- compound
- pde4 inhibitor
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
- C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C205/59—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Proceso para la preparación de compuestos que poseen actividad inhibitoria de fosfodiesterasa (PDE4) de la fórmula (I). La invención también se relaciona con el proceso para el aislamiento por cristalización del compuesto (I) y su uso para la preparación de composiciones farmacéuticas para inhalación en combinación con transportadores o vehículo adecuados. La presente invención también se relaciona con solvatos y formas cristalinas de un compuesto de la fórmula (I). El producto sintetizado es adecuado para el uso en aplicaciones farmacéuticas por ejemplo en el tratamiento de enfermedades respiratorias.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13189784 | 2013-10-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022000036A true MX2022000036A (es) | 2022-07-19 |
Family
ID=49385193
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016004834A MX370104B (es) | 2013-10-22 | 2014-10-17 | Proceso para la preparacion de un inhibidor de fosfodiesterasa (pde4). |
MX2022000030A MX2022000030A (es) | 2013-10-22 | 2016-04-14 | Proceso para la preparacion de un inhibidor de fosfodiesterasa (pde4). |
MX2022000036A MX2022000036A (es) | 2013-10-22 | 2016-04-14 | Proceso para la preparacion de un inhibidor de fosfodiesterasa (pde4). |
MX2019014408A MX2019014408A (es) | 2013-10-22 | 2016-04-14 | Proceso para la preparacion de un inhibidor de fosfodiesterasa (pde4). |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016004834A MX370104B (es) | 2013-10-22 | 2014-10-17 | Proceso para la preparacion de un inhibidor de fosfodiesterasa (pde4). |
MX2022000030A MX2022000030A (es) | 2013-10-22 | 2016-04-14 | Proceso para la preparacion de un inhibidor de fosfodiesterasa (pde4). |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019014408A MX2019014408A (es) | 2013-10-22 | 2016-04-14 | Proceso para la preparacion de un inhibidor de fosfodiesterasa (pde4). |
Country Status (29)
Country | Link |
---|---|
US (6) | US9434691B2 (es) |
EP (5) | EP3587400B1 (es) |
JP (5) | JP6458957B2 (es) |
KR (3) | KR102240865B1 (es) |
CN (3) | CN114621139A (es) |
AR (4) | AR098128A1 (es) |
AU (1) | AU2014339136C1 (es) |
BR (1) | BR112016008161B1 (es) |
CA (3) | CA3115570C (es) |
CY (1) | CY1123811T1 (es) |
DK (3) | DK3587400T3 (es) |
ES (2) | ES2759514T3 (es) |
HK (1) | HK1223926A1 (es) |
HR (2) | HRP20192152T1 (es) |
HU (2) | HUE046637T2 (es) |
IL (4) | IL285532B2 (es) |
LT (2) | LT3293176T (es) |
MX (4) | MX370104B (es) |
MY (1) | MY182559A (es) |
PH (2) | PH12016500737A1 (es) |
PL (2) | PL3293176T3 (es) |
PT (2) | PT3060551T (es) |
RS (1) | RS61558B1 (es) |
RU (1) | RU2682660C9 (es) |
SG (4) | SG10201903575UA (es) |
SI (2) | SI3060551T1 (es) |
TW (3) | TWI651305B (es) |
UA (2) | UA121853C2 (es) |
WO (1) | WO2015059050A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA112296C2 (uk) | 2010-08-03 | 2016-08-25 | К'Єзі Фармачеутічі С.П.А. | Сухий порошковий препарат, який містить інгібітор фосфодіестерази |
EP3587400B1 (en) * | 2013-10-22 | 2024-03-20 | Chiesi Farmaceutici S.p.A. | Process for the preparation of a pde4 inhibitor |
WO2018017713A1 (en) * | 2016-07-20 | 2018-01-25 | Allergan, Inc. | Methods, compositions, and compounds for treatment of dermatological and ocular conditions |
JP7361584B2 (ja) * | 2018-12-19 | 2023-10-16 | 高砂香料工業株式会社 | アミドの還元によるアミンの製造方法 |
JP6780763B2 (ja) | 2018-12-25 | 2020-11-04 | トヨタ自動車株式会社 | 内燃機関の制御装置 |
US11149615B2 (en) | 2018-12-25 | 2021-10-19 | Toyota Jidosha Kabushiki Kaisha | Control device for internal combustion engine |
CN111808029A (zh) * | 2020-08-31 | 2020-10-23 | 兰晟生物医药(苏州)有限公司 | 一种pde4抑制剂氯比普兰的制备方法 |
WO2023117985A1 (en) | 2021-12-21 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Dry powder formulations filled in an inhaler with improved resistance to humidity |
WO2023208982A1 (en) | 2022-04-27 | 2023-11-02 | Chiesi Farmaceutici S.P.A. | Crystal form of a pde4 inhibitor |
CN115304542B (zh) * | 2022-07-18 | 2024-02-02 | 湖南华纳大药厂手性药物有限公司 | 一种3-羟基吡啶的合成工艺 |
WO2024027901A1 (en) | 2022-08-02 | 2024-02-08 | Chiesi Farmaceutici S.P.A. | Predictive biomarker of clinical response to a pde4 inhibitor |
WO2024062005A1 (en) | 2022-09-22 | 2024-03-28 | Chiesi Farmaceutici S.P.A. | Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor |
WO2024062006A1 (en) | 2022-09-22 | 2024-03-28 | Chiesi Farmaceutici S.P.A. | Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor |
WO2024062007A1 (en) | 2022-09-22 | 2024-03-28 | Chiesi Farmaceutici S.P.A. | Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5935978A (en) * | 1991-01-28 | 1999-08-10 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group |
WO2001074829A1 (en) * | 2000-03-30 | 2001-10-11 | Chirotech Technology Limited | Ruthenium-diphosphine complexes and their use as catalysts |
WO2005026095A1 (en) | 2003-09-12 | 2005-03-24 | Ranbaxy Laboratories Limited | Process for the preparation of roflumilast |
JP4685861B2 (ja) * | 2004-04-29 | 2011-05-18 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | ドーパミンアゴニストとしての3−ピペリジニルイソクロマン−5−オール |
KR20070079278A (ko) | 2006-02-01 | 2007-08-06 | 삼성전자주식회사 | 수신자 제한 시스템을 이용하는 디지털 멀티미디어시스템에서 수신기의 채널 전환 시간 단축 장치 및 방법 |
EP2044023B1 (en) * | 2006-07-14 | 2011-01-19 | CHIESI FARMACEUTICI S.p.A. | Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors |
WO2008077404A1 (en) * | 2006-12-22 | 2008-07-03 | Leo Pharma A/S | Substituted acetophenones useful as pde4 inhibitors |
EP2022783A1 (en) * | 2007-08-08 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors" |
US20100015430A1 (en) | 2008-07-16 | 2010-01-21 | Outlast Technologies, Inc. | Heat Regulating Article With Moisture Enhanced Temperature Control |
EP2216327A1 (en) * | 2009-02-06 | 2010-08-11 | CHIESI FARMACEUTICI S.p.A. | Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors |
UA112296C2 (uk) * | 2010-08-03 | 2016-08-25 | К'Єзі Фармачеутічі С.П.А. | Сухий порошковий препарат, який містить інгібітор фосфодіестерази |
EP2600829B1 (en) * | 2010-08-03 | 2017-06-14 | Chiesi Farmaceutici S.p.A. | Pharmaceutical formulation comprising a phosphodiesterase inhibitor |
CN103827088B (zh) * | 2011-09-26 | 2017-10-13 | 奇斯药制品公司 | 作为磷酸二酯酶抑制剂的1‑苯基‑2‑吡啶基烷基醇的衍生物 |
WO2013087749A1 (en) * | 2011-12-16 | 2013-06-20 | Chiesi Farmaceutici S.P.A. | Potentiation induced by pde4 inhibitors in the treatment of leukemia |
CN104822659A (zh) * | 2012-12-05 | 2015-08-05 | 奇斯药制品公司 | 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇衍生物 |
US9427376B2 (en) * | 2013-10-10 | 2016-08-30 | Chiesi Farmaceutici S.P.A. | Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient |
EP3587400B1 (en) * | 2013-10-22 | 2024-03-20 | Chiesi Farmaceutici S.p.A. | Process for the preparation of a pde4 inhibitor |
EP3732164A1 (en) * | 2017-12-28 | 2020-11-04 | Chiesi Farmaceutici S.p.A. | Use of 1-phenyl-2-pyridinyl alkyl alcohol derivatives for treating cystic fibrosis |
WO2023117985A1 (en) * | 2021-12-21 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Dry powder formulations filled in an inhaler with improved resistance to humidity |
-
2014
- 2014-10-17 EP EP19183016.5A patent/EP3587400B1/en active Active
- 2014-10-17 PL PL17192278T patent/PL3293176T3/pl unknown
- 2014-10-17 BR BR112016008161-7A patent/BR112016008161B1/pt active IP Right Grant
- 2014-10-17 ES ES14795565T patent/ES2759514T3/es active Active
- 2014-10-17 RS RS20210247A patent/RS61558B1/sr unknown
- 2014-10-17 ES ES17192278T patent/ES2857629T3/es active Active
- 2014-10-17 UA UAA201604362A patent/UA121853C2/uk unknown
- 2014-10-17 DK DK19183016.5T patent/DK3587400T3/da active
- 2014-10-17 HU HUE14795565A patent/HUE046637T2/hu unknown
- 2014-10-17 RU RU2016115246A patent/RU2682660C9/ru active
- 2014-10-17 EP EP14795565.2A patent/EP3060551B1/en active Active
- 2014-10-17 HU HUE17192278A patent/HUE053112T2/hu unknown
- 2014-10-17 EP EP17192278.4A patent/EP3293176B1/en active Active
- 2014-10-17 CA CA3115570A patent/CA3115570C/en active Active
- 2014-10-17 KR KR1020167010773A patent/KR102240865B1/ko active IP Right Review Request
- 2014-10-17 US US14/516,976 patent/US9434691B2/en active Active
- 2014-10-17 EP EP20207308.6A patent/EP3798209A1/en active Pending
- 2014-10-17 WO PCT/EP2014/072334 patent/WO2015059050A1/en active Application Filing
- 2014-10-17 SG SG10201903575UA patent/SG10201903575UA/en unknown
- 2014-10-17 PL PL14795565T patent/PL3060551T3/pl unknown
- 2014-10-17 AU AU2014339136A patent/AU2014339136C1/en active Active
- 2014-10-17 SG SG10202112587RA patent/SG10202112587RA/en unknown
- 2014-10-17 EP EP22169035.7A patent/EP4059921A1/en active Pending
- 2014-10-17 PT PT147955652T patent/PT3060551T/pt unknown
- 2014-10-17 CA CA2928242A patent/CA2928242C/en active Active
- 2014-10-17 SI SI201431364T patent/SI3060551T1/sl unknown
- 2014-10-17 CN CN202210366235.7A patent/CN114621139A/zh active Pending
- 2014-10-17 IL IL285532A patent/IL285532B2/en unknown
- 2014-10-17 KR KR1020217004798A patent/KR102287596B1/ko active IP Right Grant
- 2014-10-17 CN CN201480058065.XA patent/CN105658629B/zh active Active
- 2014-10-17 DK DK17192278.4T patent/DK3293176T3/da active
- 2014-10-17 JP JP2016519348A patent/JP6458957B2/ja active Active
- 2014-10-17 MY MYPI2016000681A patent/MY182559A/en unknown
- 2014-10-17 CN CN201910622800.XA patent/CN110256338A/zh active Pending
- 2014-10-17 SI SI201431775T patent/SI3293176T1/sl unknown
- 2014-10-17 MX MX2016004834A patent/MX370104B/es active IP Right Grant
- 2014-10-17 KR KR1020217004799A patent/KR102287598B1/ko active IP Right Grant
- 2014-10-17 SG SG11201603130TA patent/SG11201603130TA/en unknown
- 2014-10-17 LT LTEP17192278.4T patent/LT3293176T/lt unknown
- 2014-10-17 SG SG10201912852YA patent/SG10201912852YA/en unknown
- 2014-10-17 DK DK14795565T patent/DK3060551T3/da active
- 2014-10-17 PT PT171922784T patent/PT3293176T/pt unknown
- 2014-10-17 LT LTEP19183016.5T patent/LT3587400T/lt unknown
- 2014-10-17 UA UAA201909177A patent/UA127453C2/uk unknown
- 2014-10-17 CA CA3115587A patent/CA3115587A1/en active Pending
- 2014-10-20 TW TW103136112A patent/TWI651305B/zh active
- 2014-10-20 TW TW107133858A patent/TWI685486B/zh active
- 2014-10-20 TW TW109102549A patent/TWI720803B/zh active
- 2014-10-20 AR ARP140103938A patent/AR098128A1/es active IP Right Grant
-
2016
- 2016-04-14 MX MX2022000030A patent/MX2022000030A/es unknown
- 2016-04-14 MX MX2022000036A patent/MX2022000036A/es unknown
- 2016-04-14 MX MX2019014408A patent/MX2019014408A/es unknown
- 2016-04-20 IL IL245220A patent/IL245220A/en active IP Right Grant
- 2016-04-20 PH PH12016500737A patent/PH12016500737A1/en unknown
- 2016-07-22 US US15/217,468 patent/US9890122B2/en active Active
- 2016-10-20 HK HK16112131.7A patent/HK1223926A1/zh unknown
-
2017
- 2017-06-11 IL IL252834A patent/IL252834B/en unknown
- 2017-11-03 US US15/802,737 patent/US10323003B2/en active Active
-
2018
- 2018-10-05 JP JP2018189627A patent/JP2019038813A/ja active Pending
-
2019
- 2019-04-23 US US16/391,952 patent/US10759761B2/en active Active
- 2019-11-29 HR HRP20192152TT patent/HRP20192152T1/hr unknown
-
2020
- 2020-01-22 PH PH12020500162A patent/PH12020500162A1/en unknown
- 2020-02-17 AR ARP200100438A patent/AR118124A2/es unknown
- 2020-07-21 US US16/934,527 patent/US11352327B2/en active Active
- 2020-10-14 JP JP2020173216A patent/JP7051970B2/ja active Active
-
2021
- 2021-02-15 CY CY20211100122T patent/CY1123811T1/el unknown
- 2021-03-01 HR HRP20210336TT patent/HRP20210336T1/hr unknown
- 2021-05-27 AR ARP210101431A patent/AR122183A2/es unknown
- 2021-05-27 AR ARP210101430A patent/AR122182A2/es unknown
- 2021-08-11 IL IL285528A patent/IL285528A/en unknown
-
2022
- 2022-02-22 JP JP2022025240A patent/JP7345581B2/ja active Active
- 2022-02-22 JP JP2022025300A patent/JP2022068321A/ja active Pending
- 2022-05-06 US US17/738,630 patent/US20220348545A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020500162A1 (en) | Process for the preparation of a pde4 inhibitor | |
IN2014MN02459A (es) | ||
PH12016500225A1 (en) | Novel quinoline-substituted compound | |
MX2015017861A (es) | Derivados de benzotiofeno como inhibidores del receptor de estrogeno. | |
TN2014000122A1 (en) | 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases | |
TN2014000128A1 (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
PH12015502737A1 (en) | Novel fused pyrimidine compound or salt thereof | |
BR112015000399A2 (pt) | derivados de pirazolil pirimidina | |
PH12015500211A1 (en) | 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | |
IN2014DN05772A (es) | ||
PH12016501977A1 (en) | 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES | |
BR112015009649A2 (pt) | composto de triazolo | |
MX2014002936A (es) | Nuevos derivados de acido betulinico con actividad antiviral. | |
MX364400B (es) | Compuestos de tetraciclina. | |
MX341577B (es) | Derivados biciclicos de pirimidin-urea o carbamato sustituidos con morfolino como inhibidores del blanco de rapamicina de mamifero. | |
MX362059B (es) | Derivados de carbamato/urea. | |
PH12014501943A1 (en) | Novel compounds for the treatment of dyslipidemia and related diseases | |
IN2015MN00045A (es) | ||
IN2014KN00849A (es) | ||
MX2013006670A (es) | Derivado de 2-carboxamida-4-piperazinil-benzofurano. | |
IN2014KN00847A (es) | ||
GEP201706680B (en) | Catechol o-methyltransferase activity inhibiting compounds |